Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies
Mounir Ait‐Khaled(ViiV Healthcare (United Kingdom)), Jean van Wyk(ViiV Healthcare (United Kingdom)), Hung‐Chin Tsai(Kaohsiung Veterans General Hospital), Richard Grove(GlaxoSmithKline (United Kingdom)), Jörg Sievers(ViiV Healthcare (United Kingdom)), Brian Wynne(Research Triangle Park Foundation), Choy Man, Juan Sierra Madero(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Andrew Zolopa(Palo Alto University), Vicente Estrada(Instituto de Salud Carlos III), Debbie Hagins(Coastal Health District), Roberto Gulminetti(University of Pavia)
Cited by 11